ETNB News and Press, 89bio Inc. From 03/17/23

2023-03-17 18:18:37 ET Summary As pegozafermin has a differentiated mode of action from Madrigal's resmetirom, 89bio, Inc. can offer an intriguing solution for NASH. Early pegozafermin data showed extremely strong liver fat reduction as well as improvement in NASH. The upcomin...

2023-03-10 08:48:58 ET 89bio press release ( NASDAQ: ETNB ): Q4 GAAP EPS of -$0.48 beats by $0.22 . As of December 31, 2022, 89bio had cash, cash equivalents, and short-term investments totaling $188.2 million compared to $150.7 million as of December 31, 2021. F...

– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 – – Feedback from FDA supports advancement of Phase 3 program for pegozafermin in SHTG; plan to initiate first of two SHTG Phase 3 trials in the second quarter of 2023 –...

2023-03-08 11:35:54 ET Summary 89bio is a clinical-stage company focused on the treatment of liver and cardio-metabolic diseases. The company's lead candidate, pegozafermin, shows strong efficacy and favorable tolerability in treating non-alcoholic steatohepatitis (NASH) and sever...

– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless of their background lipid-modifying therapy status – SAN FRANCISCO, March 04, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (...

SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data f...

SAN FRANCISCO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the Company’s Mana...

– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 – – Feedback from FDA supports advancement of Phase 3 program for pegozafermin in SHTG; plan to initiate first of two SHTG Phase 3 trials in the first half of 2023 – ...

Summary ETNB went down after Madrigal's success. It has a NASH molecule with a different mechanism of action. It has produced solid data. 89Bio ( ETNB ) is one of those NASH stocks that didn’t do too well on Madrigal’s ( MDGL ) success. It fell 30% on...

– Data from cohorts 1-6 in the proof-of-concept study showed pegozafermin was generally well tolerated and had beneficial therapeutic effect in reducing liver fat and improving markers of liver injury, fibrosis and lipids – – Pegozafermin has the poten...